Therapeutic efficacy and safety of Benazepril combined with Valsartan in the treatment of early diabetic nephropathy

WU Yundou,ZHU Li,LI Dayong,LI Meng,HUANG Yinghong,CHEN Yuanmei
DOI: https://doi.org/10.3969/j.issn.1673-7210.2013.14.028
2013-01-01
Abstract:Objective To investigate the effective program for early diabetic nephropathy(EDN).Methods 180 cases of EDN admitted into the First Hospital of Changsha City from March 2009 to May 2012 were divided into group A(60 cases),group B(60 cases) and group C(60 cases),and all patients were given hypoglycemic therapy.Moreover,group A,group B and group C received Benazepril,Valsartan,Benazepril combined with Valsartan,respectively.The therapeutic efficacy and incidence rate of adverse reactions were compared among the three groups after treatment for 20 weeks.Results Before treatment,there were no significant differences in the mean arterial pressure(MAP),urinary albumin excretion rate(UAER),urinary β2-microglobulin(β2-MG),urinary transforming growth factor-β(TGF-β) and serum cystatin C(Cys C) among the three groups(P > 0.05).After treatment,the MAP,UAER,β2-MG,TGF-β and Cys C of the three groups decreased significantly(P < 0.05),and these above indexes of the group C were significantly lower than those of the group A and the group B respectively(P < 0.05).There were no significant differences in the incidence of adverse reactions among the three groups(P > 0.05).Conclusion Benazepril combined with Valsartan in the treatment of EDN shows some advantages such as improving renal function and having good tolerance.
What problem does this paper attempt to address?